Bothra Nandini, Lin Lisa Y, Yoon Michael K
Govindram Seksaria Institute of Dacryology, L.V. Prasad Eye Institute, Hyderabad, India.
Ophthalmic Plastic Surgery Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
Semin Ophthalmol. 2025 Jan;40(1):30-34. doi: 10.1080/08820538.2024.2376620. Epub 2024 Jul 14.
To describe the management and outcomes of patients with radiation-induced acquired lacrimal duct obstructions (RALDO).
A retrospective chart review from July 2018 to December 2023 of all cases undergoing surgical intervention for RALDO by a single surgeon. Data collected included demographics, tumor type and anatomic location, radiation treatment (including radiation type, dosage, and duration), interval between radiation and reported onset of epiphora, oculoplastic clinical examination, management, and outcomes. Lacrimal irrigation was done prior to surgery in all patients.
Seventeen eyes of 16 patients with a mean age at presentation of 63.3 years and over half the patients being females (56.3%) were included in the study. The right lacrimal drainage system (LDS) was involved in 4 (23.6%), and the left side was involved in 13 (76.4%). The mean onset of epiphora symptoms after radiation was 9.5 months. The underlying tumor type were intraocular having uveal melanoma in four, cutaneous squamous cell carcinoma in 2, basal cell carcinoma involving forehead and nose in one and sino-nasal indications present in 8 patients. One patient had metastasis to the orbit and eyelid. Four patients (25%) received external beam radiotherapy (XRT) (one case had bilateral LDS involvement), 6 patients (37.5%) received intensity-modulated radiation therapy (IMRT), 5 patients (31.25%) received proton beam irradiation (PBI), and one (6.25%) received stereotactic body radiotherapy (SBRT). Mean radiation dosage was 61.31 Gy in 15 patients (data was missing in 1 patient). Punctum was effaced in 3, canalicular stenosis in 1, proximal canalicular obstruction in 8, distal canalicular obstruction in 2, and nasolacrimal duct obstruction (NLDO) in 3. Treatment was based on the site and nature of obstruction and varied from minimally invasive techniques like serial dilatation with bicanalicular silicone tube or Guibor tube to surgical interventions like dacryocystorhinostomy (DCR) or conjunctivo-dacryocystorhinostomy (C-DCR). Only 10% with primary lacrimal intubation had good response. Of the six cases that underwent C-DCR with Jones tube either as primary or secondary procedure, four cases showed improvement in epiphora (67%). Three with NLDO did well after external DCR. In total, four patients had a secondary procedure after the first failed while 7 with failed initial surgery elected against secondary surgery. The mean follow-up was 9.6 months (range 2-24 months).
In patients with RALDO, salvage treatment with silicone lacrimal intubation has poor results, CDCR with Jones tube has better results, although imperfect and in cases with NLDO, DCR has good outcomes.
描述放射性诱导获得性泪道阻塞(RALDO)患者的治疗及预后情况。
对2018年7月至2023年12月期间由同一外科医生对所有接受RALDO手术干预的病例进行回顾性病历分析。收集的数据包括人口统计学资料、肿瘤类型及解剖位置、放射治疗(包括放射类型、剂量和持续时间)、放疗与报告的溢泪发作间隔时间、眼整形临床检查、治疗方法及预后情况。所有患者在手术前均进行泪道冲洗。
本研究纳入了16例患者的17只眼,患者平均就诊年龄为63.3岁,超过半数患者为女性(56.3%)。右侧泪道系统(LDS)受累4只眼(23.6%),左侧受累13只眼(76.4%)。放疗后溢泪症状平均发作时间为9.5个月。潜在肿瘤类型包括4例眼内葡萄膜黑色素瘤、2例皮肤鳞状细胞癌、1例累及前额和鼻子的基底细胞癌以及8例鼻窦疾病。1例患者出现眼眶和眼睑转移。4例患者(25%)接受了外照射放疗(XRT)(1例双侧LDS受累),6例患者(37.5%)接受了调强放射治疗(IMRT),5例患者(31.25%)接受了质子束照射(PBI),1例患者(6.25%)接受了立体定向体部放疗(SBRT)。15例患者的平均放射剂量为61.31 Gy(1例患者数据缺失)。泪点消失3只眼,泪小管狭窄1只眼,泪小管近端阻塞8只眼,泪小管远端阻塞2只眼,鼻泪管阻塞(NLDO)3只眼。治疗方法根据阻塞部位和性质而定,从双泪小管硅胶管或吉博管连续扩张等微创技术到泪囊鼻腔吻合术(DCR)或结膜泪囊鼻腔吻合术(C-DCR)等手术干预措施不等。仅10%的原发性泪道插管患者反应良好。6例接受C-DCR联合琼斯管置入术作为初次或二次手术的患者中,4例溢泪症状改善(67%)。3例NLDO患者在外眦DCR术后效果良好。总共有4例患者在首次手术失败后接受了二次手术,而7例初次手术失败的患者选择不接受二次手术。平均随访时间为9.6个月(范围2 - 24个月)。
在RALDO患者中,硅胶泪道插管的挽救治疗效果不佳,C-DCR联合琼斯管效果较好,尽管并不完美,而对于NLDO病例,DCR效果良好。